Services
Screening
An EU-OPENSCREEN screening site will take the robust, miniaturised assay together with established orthogonal and counter screens through the high throughput screening (HTS) process, followed by confirmatory (dose response) and counter screening (identical assay without the target or with non-functional target), until a final list of confirmed hit compounds is established.
This process includes the following services:
- HTS (of the entire EU-OPENSCREEN chemical collection)
- In silico profiling, including basic chemoinformatic analysis and identification of frequent hitters and other potential false positives
- Hit selection
- Confirmatory screening, including orthogonal assay and IC/EC50 determination
- Basic counter screening
- Basic SAR based on screening data
- QC of confirmed hits for a biochemical screen, the hit confirmation process includes testing for activity in a cell-based model.
- Fragment based library screening
- Virtual screening
For more information you can watch our introductory video on high-throughput-screening (HTS) here.
Screening partner sites
CZECH REPUBLIC
Palacký University Olomouc - Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine (IMTM)
Dr. Marian Hajduch, Dr. Petr Dzubak
Institute of Molecular Genetics AS CR, v. v. i. (IMG)
Dr. Petr Bartůněk
GERMANY
Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP)/MDC Berlin - Chemical Biology – Screening Unit
Dr. Jens Peter von Kries
Helmholtz-Zentrum für Infektionsforschung GmbH (HZI) - Department of Chemical Biology (CBIO)
Prof. Dr. Mark Brönstrup
Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) – Drug Discovery - Screening Port
Dr. Philip Gribbon
SPAIN
FUNDACION MEDINA - Screening and target validation, Microbiology and Chemistry
Dr. Olga Genilloud
Prince Felipe Research Center (CIPF) - Advanced Therapies Program, Screening Platform
Dr. María J. Vicent
University of Santiago de Compostela - BioFarma Research Group
Prof. Dr. Mabel Loza
Institute for Research in Biomedicine Barcelona (IRB)
Drug Screening Platform
Israel Ramos
FINLAND
University of Helsinki, Faculty of Pharmacy - Division of Pharmaceutical Biosciences
Prof. Dr. Arto Urtti
Institute for Molecular Medicine Finland (FIMM) - High Throughput Biomedicine (HTB) unit
Prof. Dr. Päivi Tammela
University of Turku, BioCityTurku (BCT)
Prof. Dr. Michael Courtney
NORWAY
University of Bergen, Department of Biomedicine - Faculty of Medicine and Dentistry
Prof. Dr. Aurora Martinez
University of Oslo - Faculty of Medicine / Biotechnology Centre of Oslo (BiO) and Centre for Molecular Medicine (NCMM)
Dr. Johannes Landskron
Arctic University of Norway, Faculty of Biosciences, Economics and Fisheries
Prof. Dr. Jeanette H. Andersen
SINTEF Materials and Chemistry
Dr. Geir Klinkenberg
POLAND
Polish Academy of Sciences - Institute of Medical Biology, Screening laboratory for anti-viral and anti-bacterial compounds (IMB PAS)
Prof. Dr. Zbigniew J. Leśnikowski
Polish Academy of Sciences - Institute of Bioorganic Chemistry (IBCH)
Dr. Radosław Pilarski, Dr. Jacek Kolanowski
PORTUGAL
Institute of Molecular and Cell Biology - Innovation and Health Research Institute of Porto University (i3S-LA)
Prof. Dr. Antonio Pombinho
University of Coimbra - Centre for Neuroscience and Cell Biology (CNC-UC)
Dr. Miguel Mano
SWEDEN
Karolinska Institutet - Department Medical Biochemistry and Biophysics (CBCS-KI)
Dr. Anna-Lena Gustavsson
Umeå University - Chemical Biology Centre (CBCS-UmU)
Prof. Dr. Erik Chorell